鄢清元 熊巍 杨文平

【摘要】 目的：探討晚期肝癌患者索拉非尼分子靶向治疗的有效性及对疾病控制率的影响。方法：选取2019年11月-2020年11月本院收治的94例晚期肝癌患者，采用随机数字表法将其分为对照组和研究组，每组47例。对照组应用肝动脉化疗栓塞治疗，研究组在对照组基础上应用索拉非尼分子靶向治疗。比较两组疗效、免疫指标（CD3+、CD4+、CD4+/CD8+）及不良反应（肝区疼痛、手足综合征、腹泻、骨髓抑制、发热）发生情况。结果：研究组总有效率、疾病控制率均高于对照组，差异均有统计学意义（P<0.05）。治疗前，两组CD3+、CD4+、CD4+/CD8+比较，差异均无统计学意义（P>0.05）;治疗后，研究组CD3+、CD4+、CD4+/CD8+均高于对照组，差异均有统计学意义（P<0.05）。研究组不良反应发生率低于对照组，差异有统计学意义（P<0.05）。结论：晚期肝癌患者应用索拉非尼分子靶向治疗效果较好，可提高疾病控制率，提高机体免疫力，且降低不良反应发生率，安全性高，从而促进疾病转归，值得推广借鉴。

【关键词】 晚期肝癌 索拉非尼 靶向治疗 疾病控制率

Effectiveness of Molecular Targeted Therapy of Sorafenib in Advanced Liver Cancer Patients and Its Influence on Disease Control Rate/YAN Qingyuan， XIONG Wei， YANG Wenping. //Medical Innovation of China， 2021， 18（29）： -177

[Abstract] Objective： To investigate the effectiveness of molecular targeted therapy of sorafenib in advanced liver cancer patients and its influence on disease control rate. Method： A total of 94 patients with advanced liver cancer admitted to our hospital from November 2019 to November 2020 were selected， they were divided into control group and study group according to random number table method， 47 cases in each group. The control group was treated with transarterial chemoembolization， and the study group was treated with Sorafenib molecular targeted therapy based on the control group. The efficacy， immune indexes （CD3+， CD4+， CD4+/CD8+） and the occurrence of adverse reactions （liver pain， hand-foot syndrome， diarrhea， bone marrow suppression， fever） were compared between two groups. Result： The total effective rate and disease control rate in the study group were higher than those in the control group， the differences were statistically significant （P<0.05）. Before treatment， there were no significant differences in CD3+， CD4+， CD4+/CD8+ between two groups （P>0.05）; after treatment， CD3+， CD4+ and CD4+/CD8+ in the study group were higher than those in the control group， the differences were statistically significant （P<0.05）. The incidence of adverse reaction in the study group was lower than that in the control group， the difference was statistically significant （P<0.05）. Conclusion： Sorafenib molecular targeted therapy for advanced liver cancer patients has a good therapeutic effect， which can improve the disease control rate， improve the body immunity， and reduce the incidence of adverse reactions， with high safety， thus promoting the disease outcome， which is worthy of promotion and reference.

[Key words] Advanced liver cancer Solafeni Targeted therapy Disease control rate

First-authors address： Fengcheng Peoples Hospital， Fengcheng 331100， China

doi：10.3969/j.issn.1674-4985.2021.29.043

肝癌是恶性肿瘤中较为常见且多发的疾病，具有高发病率、高死亡率的特征[1]。目前，临床对于肝癌的病因尚不清楚，医师认为主要与病毒性肝炎、肝硬化等原因相关，该疾病的临床症状主要表现为恶心呕吐、肝部疼痛、上消化道出血、乏力等，严重影响患者的生活质量[2-3]。由于肝癌在发病早期较为隐匿，患者极易忽视，通常在确诊时，已处于中晚期，失去了最佳治疗时机[4-5]。现阶段，临床治疗肝癌患者的方法种类较多，疗效也大不相同，不过，对于晚期肝癌患者来说，根治性切除手术与肝移植的治疗方法效果不好，因此，探寻一种有效且安全的治疗晚期肝癌患者的方法，是现在临床医师所面临的严峻课题[6-7]。本院晚期肝癌患者在治疗时，应用索拉非尼分子靶向治疗，效果显著，现报道如下。……